Tenaya Therapeutics (TNYA) Profit After Tax (2020 - 2026)

Tenaya Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$19.3 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 28.26% year-over-year to -$19.3 million in Q1 2026; TTM through Mar 2026 was -$83.1 million, a 21.36% increase from a year earlier, with the FY2025 full-year figure at -$90.6 million, up 18.45% from the prior year.
• Profit After Tax grew to -$19.3 million in Q1 2026 per TNYA's latest filing, from -$20.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$19.3 million in Q1 2026 and bottomed at -$33.3 million in Q2 2023.
• The 5-year median for Profit After Tax is -$29.1 million (2023), against an average of -$27.5 million.
• Across the five-year window, Profit After Tax tumbled 137.1% in 2022 and climbed 28.26% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$33.1 million in 2022, then grew by 10.46% to -$29.7 million in 2023, then rose by 19.67% to -$23.8 million in 2024, then gained by 15.12% to -$20.2 million in 2025, then rose by 4.71% to -$19.3 million in 2026.
• Per Business Quant, the three latest TNYA Profit After Tax figures stand at -$19.3 million (Q1 2026), -$20.2 million (Q4 2025), and -$20.3 million (Q3 2025).